A new study of 1,443 medications found that three prescription drugs currently on the market caused unexpected changes in worms that could point to potential, unrecognized effects in humans. The research was published online on July 23, 2020 in the journal Chemosphere.
A UB study published in the journal Neurotherapeutics has validated a new pharmacological target for Alzheimer's disease. The results show the inhibition of the enzyme soluble epoxide hydrolase (sEH) in murine models with the disease reduces the neuroinflammatory process, improving the endogen response of the organism and reducing the neuronal damage and death that cause this type of dementia.
Some supposedly inert ingredients in common drugs -- such as dyes and preservatives -- may potentially be biologically active and could lead to unanticipated side effects, according to a preliminary new study by researchers from the UC San Francisco School of Pharmacy and the Novartis Institutes for BioMedical Research (NIBR).
Fighting cancer often means employing a suite of techniques to target the tumor and prevent it from growing and spreading to other parts of the body. It's no small feat -- the American Cancer Society predicts roughly 1.8 million new cases of cancer in the country in 2020, underscoring the need to identify additional ways to outsmart the runaway cells.
The creation of a silica nanocapsule could allow treatments that use light to destroy cancerous or precancerous cells in the skin to also be used to treat other types of cancer. Such are the findings of a study by INRS (Institut national de la recherche scientifique) professors Fiorenzo Vetrone and Federico Rosei, in collaboration with an international research team.
High-quality lab procedures are even more crucial to identifying effective drugs than previously thought, new research from the University of Bath has revealed.
Scientists searching for better diagnostic tests, drugs or vaccines against a virus must all begin by deciphering the structure of that virus. And when the virus in question is highly pathogenic, investigating, testing or developing these can be quite dangerous. Prof. Roy Bar-Ziv, Staff Scientist Dr. Shirley Shulman Daube, Dr. Ohad Vonshak, a former research student in Bar-Ziv's lab, and current research student Yiftach Divon have an original solution to this obstacle.
International guidelines for asthma treatment recommend clinicians find the minimum effective dose that can control symptoms, yet asthma patients are increasingly prescribed high doses of medication. A study published in PLOS Medicine by Dr. Chloe Bloom at Imperial College London, United Kingdom and colleagues found that stepping-down medication doses did not increase asthma exacerbations and could significantly reduce medication costs.
Researchers at the University of Arkansas have developed a new drug candidate that kills triple negative breast cancer cells. The discovery will help clinicians target breast cancer cells directly, while avoiding the adverse, toxic side effects of chemotherapy.
A group of Japanese scientists has succeeded in the development of modified messenger RNAs (mRNAs) that contain sulfur atoms in the place of oxygen atoms of phosphate moieties of natural mRNAs. They discovered that modified mRNAs accelerated the initiation step of the translation reactions and improved efficiency of protein synthesis by at least 20 times compared with that using natural-form mRNAs.